Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas: A report from the intergroup rhabdomyosarcoma study

Daniel M. Hays, R. Beverly Raney, William M. Crist, Walter W. Lawrence, Abdelsalam Ragab, Moody D. Wharam, Bruce Webber, Edmund Gehan, Jean Johnston, Harold M. Maurer

Research output: Contribution to journalArticle

Abstract

Fifty children with clinical group III (localized, but unresected) or clinical group IV (disseminated) soft tissue sarcomas were entered in a trial to determine if the addition of etoposide and cisplatin to standard chemotherapy regimens and irradiation (4,000 cGy) would be tolerated by pediatric patients. Responding patients had a secondary surgical procedure performed after approximately 20 weeks of therapy for the purpose of establishing histological response, determining its extent, and removing residual tumor tissue, when feasible. Such procedures were performed in 29 of 50 (58%) of these patients, ie, 20 of 31 (65%) of those in group III, and nine of 19 (47%) of those in group IV. Surgical procedures consisted of exploration of the site and biopsy (only) in 16 patients; grossly complete tumor excision in nine; and subtotal tumor excision in four. In nine patients (six in group III, three in group IV) apparent total excision of a previously unresected primary tumor mass was accomplished at second surgery. One distant but no local relapse has occurred in this group, and eight of nine have survived (five of six with identified tumor in the specimen) for a duration of 232 to 348 weeks (six > 260 wks), suggesting that among patients with primary tumors in selected sites, with either stage III or stage IV disease, excision of residual masses following intensive chemotherapy/radiotherapy regimens may favorably influence outcome. Local relapse subsequently occurred in seven of 18 patients in whom tumor tissue could not be identified in biopsy specimens or in excised masses taken from the primary site at second surgery. Thus, the pathological findings in these specimens following intensive chemotherapy/radiotherapy were not reliable predictor of subsequent local relapse.

Original languageEnglish (US)
Pages (from-to)1100-1105
Number of pages6
JournalJournal of Pediatric Surgery
Volume25
Issue number10
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Rhabdomyosarcoma
Sarcoma
Drug Therapy
Neoplasms
Recurrence
Radiotherapy
Biopsy
Residual Neoplasm
Etoposide
Cisplatin
Pediatrics

Keywords

  • Sarcoma
  • soft tissue

ASJC Scopus subject areas

  • Surgery

Cite this

Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas : A report from the intergroup rhabdomyosarcoma study. / Hays, Daniel M.; Beverly Raney, R.; Crist, William M.; Lawrence, Walter W.; Ragab, Abdelsalam; Wharam, Moody D.; Webber, Bruce; Gehan, Edmund; Johnston, Jean; Maurer, Harold M.

In: Journal of Pediatric Surgery, Vol. 25, No. 10, 1990, p. 1100-1105.

Research output: Contribution to journalArticle

Hays, Daniel M. ; Beverly Raney, R. ; Crist, William M. ; Lawrence, Walter W. ; Ragab, Abdelsalam ; Wharam, Moody D. ; Webber, Bruce ; Gehan, Edmund ; Johnston, Jean ; Maurer, Harold M. / Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas : A report from the intergroup rhabdomyosarcoma study. In: Journal of Pediatric Surgery. 1990 ; Vol. 25, No. 10. pp. 1100-1105.
@article{715f59aa4ece4748a5e727bf24c3ce57,
title = "Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas: A report from the intergroup rhabdomyosarcoma study",
abstract = "Fifty children with clinical group III (localized, but unresected) or clinical group IV (disseminated) soft tissue sarcomas were entered in a trial to determine if the addition of etoposide and cisplatin to standard chemotherapy regimens and irradiation (4,000 cGy) would be tolerated by pediatric patients. Responding patients had a secondary surgical procedure performed after approximately 20 weeks of therapy for the purpose of establishing histological response, determining its extent, and removing residual tumor tissue, when feasible. Such procedures were performed in 29 of 50 (58{\%}) of these patients, ie, 20 of 31 (65{\%}) of those in group III, and nine of 19 (47{\%}) of those in group IV. Surgical procedures consisted of exploration of the site and biopsy (only) in 16 patients; grossly complete tumor excision in nine; and subtotal tumor excision in four. In nine patients (six in group III, three in group IV) apparent total excision of a previously unresected primary tumor mass was accomplished at second surgery. One distant but no local relapse has occurred in this group, and eight of nine have survived (five of six with identified tumor in the specimen) for a duration of 232 to 348 weeks (six > 260 wks), suggesting that among patients with primary tumors in selected sites, with either stage III or stage IV disease, excision of residual masses following intensive chemotherapy/radiotherapy regimens may favorably influence outcome. Local relapse subsequently occurred in seven of 18 patients in whom tumor tissue could not be identified in biopsy specimens or in excised masses taken from the primary site at second surgery. Thus, the pathological findings in these specimens following intensive chemotherapy/radiotherapy were not reliable predictor of subsequent local relapse.",
keywords = "Sarcoma, soft tissue",
author = "Hays, {Daniel M.} and {Beverly Raney}, R. and Crist, {William M.} and Lawrence, {Walter W.} and Abdelsalam Ragab and Wharam, {Moody D.} and Bruce Webber and Edmund Gehan and Jean Johnston and Maurer, {Harold M.}",
year = "1990",
doi = "10.1016/0022-3468(90)90228-2",
language = "English (US)",
volume = "25",
pages = "1100--1105",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas

T2 - A report from the intergroup rhabdomyosarcoma study

AU - Hays, Daniel M.

AU - Beverly Raney, R.

AU - Crist, William M.

AU - Lawrence, Walter W.

AU - Ragab, Abdelsalam

AU - Wharam, Moody D.

AU - Webber, Bruce

AU - Gehan, Edmund

AU - Johnston, Jean

AU - Maurer, Harold M.

PY - 1990

Y1 - 1990

N2 - Fifty children with clinical group III (localized, but unresected) or clinical group IV (disseminated) soft tissue sarcomas were entered in a trial to determine if the addition of etoposide and cisplatin to standard chemotherapy regimens and irradiation (4,000 cGy) would be tolerated by pediatric patients. Responding patients had a secondary surgical procedure performed after approximately 20 weeks of therapy for the purpose of establishing histological response, determining its extent, and removing residual tumor tissue, when feasible. Such procedures were performed in 29 of 50 (58%) of these patients, ie, 20 of 31 (65%) of those in group III, and nine of 19 (47%) of those in group IV. Surgical procedures consisted of exploration of the site and biopsy (only) in 16 patients; grossly complete tumor excision in nine; and subtotal tumor excision in four. In nine patients (six in group III, three in group IV) apparent total excision of a previously unresected primary tumor mass was accomplished at second surgery. One distant but no local relapse has occurred in this group, and eight of nine have survived (five of six with identified tumor in the specimen) for a duration of 232 to 348 weeks (six > 260 wks), suggesting that among patients with primary tumors in selected sites, with either stage III or stage IV disease, excision of residual masses following intensive chemotherapy/radiotherapy regimens may favorably influence outcome. Local relapse subsequently occurred in seven of 18 patients in whom tumor tissue could not be identified in biopsy specimens or in excised masses taken from the primary site at second surgery. Thus, the pathological findings in these specimens following intensive chemotherapy/radiotherapy were not reliable predictor of subsequent local relapse.

AB - Fifty children with clinical group III (localized, but unresected) or clinical group IV (disseminated) soft tissue sarcomas were entered in a trial to determine if the addition of etoposide and cisplatin to standard chemotherapy regimens and irradiation (4,000 cGy) would be tolerated by pediatric patients. Responding patients had a secondary surgical procedure performed after approximately 20 weeks of therapy for the purpose of establishing histological response, determining its extent, and removing residual tumor tissue, when feasible. Such procedures were performed in 29 of 50 (58%) of these patients, ie, 20 of 31 (65%) of those in group III, and nine of 19 (47%) of those in group IV. Surgical procedures consisted of exploration of the site and biopsy (only) in 16 patients; grossly complete tumor excision in nine; and subtotal tumor excision in four. In nine patients (six in group III, three in group IV) apparent total excision of a previously unresected primary tumor mass was accomplished at second surgery. One distant but no local relapse has occurred in this group, and eight of nine have survived (five of six with identified tumor in the specimen) for a duration of 232 to 348 weeks (six > 260 wks), suggesting that among patients with primary tumors in selected sites, with either stage III or stage IV disease, excision of residual masses following intensive chemotherapy/radiotherapy regimens may favorably influence outcome. Local relapse subsequently occurred in seven of 18 patients in whom tumor tissue could not be identified in biopsy specimens or in excised masses taken from the primary site at second surgery. Thus, the pathological findings in these specimens following intensive chemotherapy/radiotherapy were not reliable predictor of subsequent local relapse.

KW - Sarcoma

KW - soft tissue

UR - http://www.scopus.com/inward/record.url?scp=0025086199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025086199&partnerID=8YFLogxK

U2 - 10.1016/0022-3468(90)90228-2

DO - 10.1016/0022-3468(90)90228-2

M3 - Article

C2 - 2262867

AN - SCOPUS:0025086199

VL - 25

SP - 1100

EP - 1105

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 10

ER -